Rentokil hit by N.America woes; no immediate re-listing plans
2024 N.America organic revenue growth seen at lower end of range
No immediate plans to move listing to US
Shares fell as much as 7%
Rewrites, adds share milestones
By Yamini Kalia
July 25 (Reuters) -British pest control company Rentokil Initial RTO.L said on Thursday it expected underlying revenue at its North American business - the group's largest - to come in at the lower end of its forecast, sending its shares as much as 7% lower.
The company, which made about 60% of its revenue in North America last year, also said it had no immediate plans to move its listing to the United States, as some analysts had speculated.
"Going forward, the board will continue to keep the Group's listing structure under review to ensure that the strength of the Group's underlying financial performance and its prospects are appropriately valued," it said in a statement.
Rentokil's shares have fallen about 20% since it flagged softer demand in North America last October.
Earlier this month, the shares rose on reports ex-BT chief Philip Jansen was looking to buy the firm. They also jumped in June on news that activist investor Nelson Peltz's Trian Fund Management had built a stake in the company and was interested in discussing "ideas and initiatives".
In March, Rentokil said it expected organic revenue in North America to rise by 2-4% this year. On Thursday, it said it now expected revenue growth there at the lower end of this range.
For the second quarter, the key North American pest control business posted a 0.5% rise in organic revenue, compared with the previous quarter.
"Investors are ostensibly reacting to the muted quarter-on-quarter improvement in organic growth for the beleaguered North America pest control business," said Morningstar analyst Grant Slade.
Rentokil and rival Rollins ROL.N account for roughly half of the U.S. pest control market, with Rentokil the larger player after it bought U.S. rival Terminix.
Rollins posted a 7.7% organic revenue growth in the second quarter.
"Relative to the growth of the broader market, Rentokil is underperforming the peers while Rollins continues to outperform," Slade added.
Reporting by Yamini Kalia in Bengaluru; Editing by Sherry Jacob-Phillips and Mark Potter
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
